Pharmacometrics evaluation and antimicrobial efficacy of standard meropenem dosing in gram negative sepsis: A longitudinal, sigle center study

Manipal Center for Infectious Diseases MAC ID0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients diagnosed with sepsis or septic shock: suspicion of infection and microbiological sampling undertaken, received meropenem, vasopressor therapy needed to elevate mean arterial pressure >=65 mmHg and lactate >2mmol/L (18mg/dL) despite adequate fluid resuscitation
•2. Confirmed infection by Gram negative organism (Klebsiella pneumoniae, Escherichia coli and/or Pseudomonas aeruginosa)

•1.Pregnant or lactating women
•2.Documented hypersensitivity to carbapenems
•3.Patients with an anticipated hospitalization of <=2 days
•4.Patients with chronic kidney disease (CKD)
•5.Extra-corporeal circulation in the month preceding inclusion in the case of cardiac surgery
•6.Blood transfusion >4 units in past week
•7.Patient with restricted liberty or under legal protection
•8.Inability to consent the patient or next of kin
•9.Second admission to ICU or previous enrolment in study (within same hospital admission)
•10.Transfer from other hospital ICUs (if stay >24 hrs)

发起方

Manipal Center for Infectious Diseases MAC ID